文献速递前列腺增生与排尿功能障碍

聚二甲基硅氧烷注射治疗女性压力性尿失禁的3年随访结果

Efficacy and safety of polydimethylsiloxane injection (Macroplastique® ) for the treatment of female stress urinary incontinence: results of a series of 85 patients with ≥3 years of follow-up.
PubMed 文献 · BJU Int · 2018-10-16

这项前瞻性队列研究纳入85例经尿动力学确诊的单纯性压力性尿失禁女性,评估聚二甲基硅氧烷注射的长期疗效与安全性。3年随访时49%患者主观治愈,47%客观治愈,疗效稳定,并发症率极低;既往根治性盆腔手术和术者技术低是失败独立预测因素。

要点

  • 3年主观治愈率49%,客观治愈率47%,疗效随时间稳定。
  • 并发症率极低,可作为压力性尿失禁的可接受替代治疗。
  • 既往根治性盆腔手术和术者技术低是失败独立预测因素。

核心结论

  • 聚二甲基硅氧烷注射治疗女性压力性尿失禁3年结果稳定,并发症率极低,可作为可接受的替代治疗。

研究设计与样本

  • 单中心泌尿妇科单元的前瞻性观察性队列研究,连续纳入85例经尿动力学确诊的单纯性压力性尿失禁女性,随访至少3年。

主要发现

  • 3年随访时85例(100%)均可评估,手术结局无显著变化。
  • 42/85例(49%)主观治愈(P=0.67),40/85例(47%)客观治愈,客观治愈率无显著恶化(P=0.3)。
  • 既往根治性盆腔手术和术者技术低与治疗失败风险显著相关,多变量分析证实二者独立预测主观和客观失败。

关键数值与推荐

  • 主观治愈:42/85例(49%),P=0.67。
  • 客观治愈:40/85例(47%),客观治愈率随时间无显著恶化,P=0.3。

临床怎么用

  • 对于单纯性压力性尿失禁女性,可考虑聚二甲基硅氧烷注射作为替代治疗。
  • 术前应评估既往根治性盆腔手术史,并由技术熟练的术者操作以降低失败风险。

局限性

  • 单中心观察性研究,样本量85例,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the long-term efficacy and safety of polydimethylsiloxane injection (Macroplastique® , Cogentix Medical, Orangeburg, New York, USA) for the treatment of female stress urinary incontinence (SUI), with a minimum follow-up of 3 years. PATIENTS AND METHODS: This is an observational analytical prospective cohort study conducted in a single uro-gynaecological unit. All consecutive women with urodynamically confirmed pure SUI treated with the Macroplastique procedure, were included. Data regarding patient outcomes (International Consultation on Incontinence Questionnaire-Short Form, Patient Global Impression of Improvement, and patient satisfaction scores), objective cure rates, and adverse events were collected during follow-up. Uni- and multivariable analyses were performed to investigate outcomes. Multiple logistic regression was performed to identify factors involved in the risk of failure of the procedures or recurrence of SUI. RESULTS: In all, 85 women had the Macroplastique procedure. At the 3-year follow-up, all 85 (100%) patients were available for the evaluation. We did not find any significant change in the surgical outcomes during this time. At 3 years after surgery, 42 of 85 patients (49%) declared themselves cured (P = 0.67). Similarly, at the 3-year evaluation, 40 of 85 patients (47%) were objectively cured. There was no significant deterioration of objective cure rates over time (P = 0.3). A history of radical pelvic surgery and a low surgeon's skill were significantly associated with the risk of failure of Macroplastique. The multivariate analysis confirmed these findings; a previous history of radical pelvic surgery and a low surgeon's skill independently predicted the subjective and objective failure of Macroplastique. CONCLUSIONS: The 3-year results of this study showed that Macroplastique could be an acceptable alternative for the treatment of SUI with stable results over time and a negligible complication rate.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Serati M, Soligo M, Braga A, et al. Efficacy and safety of polydimethylsiloxane injection (Macroplastique® ) for the treatment of female stress urinary incontinence: results of a series of 85 patients with ≥3 years of follow-up. BJU Int. 2018. PMID: 30253026. doi:10.1111/bju.14550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。